Corrigendum: Decrease in social zeitgebers is associated with worsened delayed sleep-wake phase disorder: findings during the pandemic in Japan

[This corrects the article DOI: 10.3389/fpsyt.2022.898600.].

In the published article, there was an error in Table 1 as published. The entry for Developmental disorders, originally listed as 11 (21.7), is incorrect; the correct figure is Developmental disorders,11 (18.3). Similarly, the entry for Psychostimulants, previously stated as 5 (7.4), is incorrect; the accurate figure is Psychostimulants, 5 (8.3). The entry for combined therapy with both (n = 5) is also incorrect; the correct number is combined therapy with both (n = 6). Finally, the entry for Antipsychotics was listed as 15 (25) without decimal point, but the correct version is Antipsychotics, 15 (25.0). The corrected Table 1 and its caption appear below.
In the published article, there was an error in Table 3 as published. Within the footnotes, the entry for combination therapy of both, originally listed as (n = 5), is incorrect; the correct number is combination therapy of both (n = 6). Additionally, the footnote c) was missing the information about the combination of obstructive sleep apnea with sleep-related movement disorders, which should have been mentioned as (n = 1). The corrected Table 3 and its caption appear below.
In the published article, there was also an error in the text. The term "? 2 test" was incorrect, and the correct term is the "χ 2 test".
An amendment has been made in the Methods section, specifically the Statistical analysis part, on Line 2.
Originally, the sentence stated: "Based on baseline severity, a comparison between mild DSWPD and moderate-to-severe DSWPD was made using the ? 2 test for categorical variables and the Mann-Whitney U-test for the following continuous variables:" The corrected sentence appears below: "Based on baseline severity, a comparison between mild DSWPD and moderate-to-severe DSWPD was made using the χ 2 test for categorical variables and the Mann-Whitney U-test for the following continuous variables:" The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
. /fpsyt. . Psychotropic medications other than ramelteon and melatonin 2.400 (0.837-6.882) n.s. a Using the difference in CGI-S scores before and during the COVID-19 pandemic, we defined the worsened group as one or more points increase. b Relative risks approximated to odds ratios. c Including obstructive sleep apnea (n = 11), central disorders of hypersomnolence (n = 3), sleep-related movement disorders (n = 2), parasomnias (n = 1), and combination of obstructive sleep apnea with sleep-related movement disorders (n = 1). d Including use of ramelteon or melatonin (n = 36), bright light therapy (n = 1), and combination therapy of both (n = 6).